S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free mirm Stock Alerts
$23.81
+0.24 (+1.02%)
(As of 04:37 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Mirum Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$51.70
117.14% Upside
High Forecast$72.00
Average Forecast$51.70
Low Forecast$35.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.70$52.11$54.13$49.00
Predicted Upside117.14% Upside83.15% Upside83.85% Upside123.78% Upside
Get Mirum Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.

MIRM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MIRM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Mirum Pharmaceuticals Stock vs. The Competition

TypeMirum PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside119.35% Upside928.11% Upside12.31% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/17/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$48.00+99.34%
4/2/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$58.00+131.08%
3/18/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$44.00 ➝ $43.00+62.51%
3/14/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$69.00 ➝ $72.00+173.76%
2/29/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$35.00+22.12%
12/19/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetStrong-Buy ➝ Strong-Buy$78.00 ➝ $64.00+117.80%
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight$37.00+14.48%
11/13/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$60.00+109.72%
10/17/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform$62.00+112.62%
10/3/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$35.00 ➝ $38.00+29.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:33 PM ET.

MIRM Price Target - Frequently Asked Questions

What is Mirum Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Mirum Pharmaceuticals stock is Buy based on the current 8 buy ratings and 1 strong buy rating for MIRM. The average twelve-month price prediction for Mirum Pharmaceuticals is $51.70 with a high price target of $72.00 and a low price target of $35.00. Learn more on MIRM's analyst rating history.

Do Wall Street analysts like Mirum Pharmaceuticals more than its competitors?

Analysts like Mirum Pharmaceuticals more than other Medical companies. The consensus rating for Mirum Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how MIRM compares to other companies.

Does Mirum Pharmaceuticals's stock price have much upside?

According to analysts, Mirum Pharmaceuticals's stock has a predicted upside of 85.53% based on their 12-month stock forecasts.

What analysts cover Mirum Pharmaceuticals?

Mirum Pharmaceuticals has been rated by Cantor Fitzgerald, HC Wainwright, JMP Securities, Stifel Nicolaus, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MIRM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
How Biden has already won 2024
Porter & Company